Corvus Pharmaceuticals (NASDAQ:CRVS) Earns “Buy” Rating from HC Wainwright

Corvus Pharmaceuticals (NASDAQ:CRVS)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a note issued to investors on Wednesday,Benzinga reports. They currently have a $11.00 target price on the stock. HC Wainwright’s target price indicates a potential upside of 226.41% from the stock’s previous close. HC Wainwright also issued estimates for Corvus Pharmaceuticals’ FY2028 earnings at $0.11 EPS and FY2029 earnings at $0.44 EPS.

Corvus Pharmaceuticals Stock Up 0.6 %

NASDAQ CRVS opened at $3.37 on Wednesday. The stock has a market capitalization of $216.55 million, a PE ratio of -3.62 and a beta of 0.91. Corvus Pharmaceuticals has a 12-month low of $1.30 and a 12-month high of $10.00. The company has a 50 day moving average price of $4.64 and a two-hundred day moving average price of $6.06.

Corvus Pharmaceuticals (NASDAQ:CRVS) last released its quarterly earnings data on Tuesday, March 25th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.06). As a group, equities analysts anticipate that Corvus Pharmaceuticals will post -0.63 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in CRVS. Virtus ETF Advisers LLC acquired a new stake in Corvus Pharmaceuticals in the 4th quarter worth approximately $47,000. Nwam LLC bought a new position in shares of Corvus Pharmaceuticals in the third quarter valued at approximately $53,000. PKS Advisory Services LLC acquired a new stake in shares of Corvus Pharmaceuticals in the fourth quarter worth $56,000. Alpine Global Management LLC bought a new stake in shares of Corvus Pharmaceuticals during the 4th quarter worth $62,000. Finally, ExodusPoint Capital Management LP acquired a new position in Corvus Pharmaceuticals in the 4th quarter valued at $72,000. Institutional investors and hedge funds own 46.64% of the company’s stock.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.